Pfizer generated free cash flow of $10.4 billion in the 12 months ending Sept. 30, 2025. During this period, the pharma giant ...

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

Trading at a bit under $25 apiece, Pfizer 's (NYSE: PFE) shares appear tentatively cheap. However, the pharmaceutical giant reached these levels because it has faced significant headwinds, resulting ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market ...

This makes Pfizer a potentially cheap stock to buy while collecting a solid dividend. It's generated about $14 billion in ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

It's quite possible for the new year to fulfill this ambitious name. Investing $122,100 in these three high-yield dividend ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...

We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December ...

Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...